-
Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial
Monday, February 1, 2016 - 3:49pm | 251Read More...Shares of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) hit a new 52-week low of $4.72 on Monday and was trading lower by more than 4 percent. Ariad Pharmaceuticals announced earlier in the day that the U.S. Food and Drug Administration has completed its review of the company's Investigational New...
-
Top Trending Tickers On StockTwits For March 14
Friday, March 14, 2014 - 9:40am | 747Read More...Here's a look at the top tickers trending on StockTwits.com. Teva Pharmaceutical: CEO hosts UK and Israeli leaders Teva Pharmaceuticals (NASDAQ: TEVA) announced a collaboration between Teva and the United Kingdom Government's National Health Service National Institute for Health Research (NIHR)...
-
Market Wrap For February 21: Markets End The Week On A Negative Note
Friday, February 21, 2014 - 5:48pm | 2876Read More...U.S. stocks finished the week slightly lower as investors gave today's poor housing data a slack, and blame it on the weather. “Investors are willing to cut the market some slack because of the weather; I'm keeping my fingers crossed that the economy heats up as the weather warms up,” Jack...
-
Ariad Pharmaceuticals Able to Continue Its EU Iclusig Sales
Friday, November 22, 2013 - 5:05pm | 328Read More...Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) surged Friday, after the company revealed advisors to European Union regulators believe the company's Iclusig cancer drug should stay on the European market. Iclusig is used to treat two rare types of leukemia. Iclusig is Ariad's only product and...
